TR200102766T2 - Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar - Google Patents

Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar

Info

Publication number
TR200102766T2
TR200102766T2 TR2001/02766T TR200102766T TR200102766T2 TR 200102766 T2 TR200102766 T2 TR 200102766T2 TR 2001/02766 T TR2001/02766 T TR 2001/02766T TR 200102766 T TR200102766 T TR 200102766T TR 200102766 T2 TR200102766 T2 TR 200102766T2
Authority
TR
Turkey
Prior art keywords
tryptase inhibitors
ketones used
heterocyclic ketones
peptidyl
prevention
Prior art date
Application number
TR2001/02766T
Other languages
English (en)
Inventor
J. Costanzo Michael
E. Maryanoff Bruce
C. Yabut Stephen
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of TR200102766T2 publication Critical patent/TR200102766T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bulus iltihapli hücre serin proteaz inhibitörleri olan bir dizi peptidil heterosiklik ketinlar ve bilesimleri ve çesitli bagisiklik nedenli iltihapli rahatsizliklarin tedavisi ve önlenmesi için yöntemlerle ilgilidir. Daha ayrintili olarak, bu terkipler triptazin güçlü ve selektif inhibitörleri olmalari nedeniyle astim ve alerjik rinit gibi solunum yolu baglantili iltihapli hastaliklarin tedavisi ve önlenmesinde etkilidir.
TR2001/02766T 1999-01-27 2000-01-13 Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar TR200102766T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11760299P 1999-01-27 1999-01-27

Publications (1)

Publication Number Publication Date
TR200102766T2 true TR200102766T2 (tr) 2001-12-21

Family

ID=22373811

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02766T TR200102766T2 (tr) 1999-01-27 2000-01-13 Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar

Country Status (24)

Country Link
US (2) US6469036B1 (tr)
EP (1) EP1147097A1 (tr)
JP (1) JP2002535394A (tr)
KR (1) KR20010110422A (tr)
CN (1) CN1353701A (tr)
AR (1) AR022427A1 (tr)
AU (1) AU3208500A (tr)
BG (1) BG105762A (tr)
BR (1) BR0007778A (tr)
CA (1) CA2361479A1 (tr)
CZ (1) CZ20012722A3 (tr)
EA (1) EA200100815A1 (tr)
EE (1) EE200100391A (tr)
HK (1) HK1038561A1 (tr)
HR (1) HRP20010601A2 (tr)
HU (1) HUP0201295A3 (tr)
IL (1) IL144577A0 (tr)
NO (1) NO20013666L (tr)
SK (1) SK10742001A3 (tr)
TR (1) TR200102766T2 (tr)
TW (1) TWI229669B (tr)
WO (1) WO2000044733A1 (tr)
YU (1) YU61401A (tr)
ZA (1) ZA200106995B (tr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
ATE329899T1 (de) * 2000-03-27 2006-07-15 Applied Research Systems Pharmazeutisch wirksame pyrrolidin-derivate als bax-inhibitoren
AU2001256209B2 (en) * 2000-03-27 2006-02-16 Merck Serono Sa Pharmaceutically active pyrrolidine derivatives
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6797461B2 (en) * 2000-10-27 2004-09-28 Promega Corporation Tryptase substrates and assay for tryptase activity using same
US20040048772A1 (en) * 2001-01-05 2004-03-11 Ryusuke Nakagiri Preventives for arthritis
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
GB0103765D0 (en) * 2001-02-15 2001-04-04 Affitech As Assay
AU2002352382A1 (en) * 2001-12-13 2003-06-23 Kowa Company Ltd Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity
AU2003237224A1 (en) * 2002-05-29 2003-12-19 Merck And Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
DE10249304B4 (de) * 2002-10-22 2006-09-28 Cytec Surface Specialties Germany Gmbh & Co. Kg Wäßrige Beschichtungsmittel
US7205384B2 (en) * 2003-08-05 2007-04-17 Ortho-Mcneil Pharmaceutical Inc. Process for preparing peptidyl heterocyclic ketone derivatives
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
KR20070001976A (ko) * 2004-02-10 2007-01-04 얀센 파마슈티카 엔.브이. 알파４ 인테그린의 길항제로서의 피리다지논 우레아
US20060063930A1 (en) * 2004-08-20 2006-03-23 Agoston Gregory E Compositions and methods comprising proteinase activated receptor antagonists
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
CN101443348A (zh) * 2006-05-23 2009-05-27 Irm责任有限公司 作为通道活化蛋白酶抑制剂的化合物和组合物
US7951823B2 (en) * 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
CN101646437A (zh) * 2007-02-09 2010-02-10 Irm责任有限公司 作为通道活化蛋白酶抑制剂的化合物和组合物
EA016327B1 (ru) 2007-02-09 2012-04-30 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
KR101131238B1 (ko) 2007-02-09 2012-03-30 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
ES2351323B1 (es) * 2009-06-26 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
EP2714716B1 (en) 2011-06-02 2018-04-11 Socpra Sciences Santé Et Humaines S.E.C. Matriptase inhibitors and uses thereof against orthomyxoviridae infections
CN103145598B (zh) * 2011-12-07 2014-10-15 北京京卫顺康医药科技发展有限公司 一种奥沙西罗晶体及含有该晶体的组合物
JP6526652B2 (ja) * 2013-10-29 2019-06-05 ビオマリン プハルマセウトイカル インコーポレイテッド グルコシルセラミドシンターゼ阻害剤としてのｎ−（１−ヒドロキシ−３−（ピロリジニル）プロパン−２−イル）ピロリジン−３−カルボキサミド誘導体
MX378266B (es) 2014-10-06 2025-03-10 Lighthouse Pharmaceuticals Inc Inhibidores de gingipaina de lisina.
WO2016144654A1 (en) * 2015-03-09 2016-09-15 Washington University Inhibitors of growth factor activation enzymes
CN108602787A (zh) * 2015-11-09 2018-09-28 库特克希米公司 精氨酸牙龈卟啉菌蛋白酶的抑制剂
CN109983012B (zh) 2016-09-16 2023-12-01 莱特豪斯制药公司 赖氨酸牙龈蛋白酶的酮抑制剂
CN110944637A (zh) * 2017-05-10 2020-03-31 库特克希米公司 氨基吡啶化合物及其制备方法和使用方法
US12545671B2 (en) 2021-07-15 2026-02-10 National Center For Global Health And Medicine Compound having biological activity such as antiviral activity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525623A (en) 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
JPH0820597A (ja) 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
AP9701004A0 (en) 1994-12-22 1997-07-31 Iaf Biochem Int Low molecular weight bicyclic thrombin inhibitors.
WO1996019491A1 (en) 1994-12-22 1996-06-27 Biochem Pharma Inc. Heterocyclic keto arginine peptides as thrombin inhibitors
WO1996030396A1 (en) 1995-03-24 1996-10-03 Molecumetics Ltd. β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS
JPH10508034A (ja) 1995-03-24 1998-08-04 モレキュメティックス リミテッド βシート模倣物および生物学的に活性なペプチドまたはタンパク質のインヒビターとしてのその使用
GB9510264D0 (en) 1995-05-22 1995-07-19 Iaf Biochem Int Low molecular weight bicyclic-urea type thrombin inhibitors
US5827866A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827860A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5523308A (en) 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6069130A (en) * 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
IL119466A (en) * 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
NZ334227A (en) 1996-08-05 2000-10-27 Molecumetics Ltd Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
AU4172397A (en) 1996-09-06 1998-03-26 Biochem Pharma Inc. Lactam inhibitors of thrombin
US5827886A (en) * 1997-05-07 1998-10-27 Thione International, Inc. Composition for relief of arthritis-induced symptoms
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
WO1999026925A1 (en) 1997-11-26 1999-06-03 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitors comprising heterocyclic amide compounds
BR9814284A (pt) 1997-12-16 2000-10-03 Johnson & Johnson Composições e métodos para regulação de fagocitose e expressão de icam-1

Also Published As

Publication number Publication date
TWI229669B (en) 2005-03-21
AR022427A1 (es) 2002-09-04
EP1147097A1 (en) 2001-10-24
HUP0201295A2 (en) 2002-09-28
EE200100391A (et) 2002-10-15
HUP0201295A3 (en) 2002-10-28
CZ20012722A3 (cs) 2002-08-14
BR0007778A (pt) 2002-06-04
YU61401A (sh) 2005-07-19
NO20013666D0 (no) 2001-07-26
AU3208500A (en) 2000-08-18
BG105762A (en) 2002-03-29
HRP20010601A2 (en) 2002-08-31
EA200100815A1 (ru) 2002-08-29
US6469036B1 (en) 2002-10-22
ZA200106995B (en) 2002-11-25
CN1353701A (zh) 2002-06-12
JP2002535394A (ja) 2002-10-22
WO2000044733A1 (en) 2000-08-03
HK1038561A1 (zh) 2002-03-22
KR20010110422A (ko) 2001-12-13
NO20013666L (no) 2001-09-26
CA2361479A1 (en) 2000-08-03
IL144577A0 (en) 2002-05-23
US7132418B2 (en) 2006-11-07
SK10742001A3 (sk) 2002-08-06
US20030008829A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
TR200102766T2 (tr) Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar
ATE457313T1 (de) Bicyclische heterocyclische p-38-kinase- inhibitoren
TR200103390T2 (tr) Proteaz inhibitörleri olan yeni bileşikler ve terkipler.
ATE189211T1 (de) Zusammensetzungen und verfahren zur behandlung von durch mast-zellen verursachten krankheiten
SE0201980D0 (sv) Novel compounds
NO20070201L (no) Seksleddede heterocykler anvendelige som serinproteaseinhibitorer
WO2005099709A3 (en) Bicyclic heterocycles useful as serine protease inhibitors
ATE439837T1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
UA74372C2 (uk) Інгібітори серинових протеаз, фармацевтична композиція на їх основі
ATE268766T1 (de) Stickstoff enthaltende heterobicyclen als factor xa inhibitoren
CY1110527T1 (el) Διαρυλ ενωσεις ως αναστολεις πρωτεασης σερινης
NO20005261L (no) Nye heterocyklisk substituerte amider med cystein-protease- inhiberende virkning
ATE303989T1 (de) Inhibitoren von serin proteasen
ATE365729T1 (de) Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion
EP1611120A4 (en) NEW METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
SE0203712D0 (sv) Novel compounds
EA200501463A1 (ru) Новые соединения фосфоновой кислоты в качестве ингибиторов серинпротеаз
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
MEP48708A (en) Phosphonic acid compounds as inhibitors of serine proteases
EP1546326A4 (en) NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
ATE241383T1 (de) Behandlung von allergischen zuständen mit cystein-und serin-proteinase inhibitoren
NO20091619L (no) Nye tetracykliske inhibitorer av cystein-proteaser, farmasoytiske blandinger derav og deres farmasoytiske anvendelse
TW200612952A (en) Six-membered heterocycles useful as serine protease inhibitors